Biobadamérica promotes the use of biological and biosimilar drugs in Latin America

Biosimilars/General | Posted 25/06/2021 post-comment0 Post your comment

In 2007, the Spanish Society of Rheumatology (Sociedad Española de Reumatología, SER) created the Biobadamérica, an international collaborative project to promote the implementation of national safety registries for the use of biological and biosimilar drugs in Latin American countries [1]. 

RT UK Registries 2017 COVER V17A17LB

SER would bring to the Biobadamérica project its experience with Biobadaser (the Spanish registry of adverse events of biological therapies in rheumatic diseases created in 2000), as well as the structure of a fully consolidated database that has been extensively tested in Spain.

The Biobadamérica project implies the collaboration of researchers from Argentina, Brazil, Dominican Republic, Mexico, Paraguay and Uruguay, with Colombia and Chile expected to join.

The main objectives of Biobadamérica are:

  1. To collect the highest number of patient data
  2. To put professionals from different countries in contact with each other
  3. To encourage the publication of scientific articles

As Dr Federico Díaz, Director of the SER Research Unit and rheumatologist at the University Hospital of the Canary Islands, announced in a meeting with the SER in 2016, 'this scientific collaboration has already enabled the production of joint publications, and further cooperation is expected to be developed between countries participating in the project to improve the experience in terms of safety and effectiveness with the use of biological and biosimilar drugs for the treatment of rheumatic diseases'.

Editor’s comment
Readers interested to learn more about the implementation of a treatment registry for a biosimilar in Argentina are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper relating to generics or biosimilars development in Latin American countries in English or Spanish to GaBI Journal – an independent, peer reviewed academic journal – please submit your manuscript here.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
1.6 – CiteScoreTracker 2021 (Last updated on 4 June 2021)

Submit a manuscript to GaBI Journal

Related article
Spanish Society of Rheumatology issues position statement on biosimilars

LATIN AMERICAN FORUM

The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Un nuevo decreto modifica varios aspectos del sistema de aprobación regulatoria de biosimilares en México

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Un nuevo decreto modifica varios aspectos del sistema de aprobación regulatoria de biosimilares en México

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: Sociedad Española de Reumatología

comment icon Comments (0)
Post your comment
Related content
PANLAR issues consensus statement on biosimilars
Question-Fimea-V15E29
Biosimilars/General Posted 16/07/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010